Pharmacogenetics in anticoaguation dosage adjustment

Warfarin nowadays is the standard of anticoagulation therapy for patients with prosthetic heart valves, but the clinical usage of warfarin is limited due to large spectrum of side effects and unpredictable therapeutic effect. According to published data, all types of complications (bleeding and thrombosis) occur in almost 30% of patients receiving warfarin at a regular base. Pharmacogenetic testing, when timely performed, can reveal the patients requiring individual dose adjustment and thus reduce the percentage of complications. In our study we compare to strategies of dose adjustment in female 61 y.o. patient with prosthetic aortic and mitral valves.